Analysts are bullish on Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and Celldex Therapeutics, Inc. (NASDAQ:CLDX) as Valeant’s CEO has returned from sick leave and …
Biotech stocks are notoriously volatile as a pipeline update or FDA announcement can instantly send share prices through the roof. Below, analysts weigh …
Celldex Therapeutics, Inc. (NASDAQ:CLDX) reported business and financial highlights for the fourth quarter and year ended December 31, 2015.
Healthcare analysts weighed in on development-stage company Celldex Therapeutics, Inc. (NASDAQ:CLDX) and biopharmaceutical firm Mast Therapeutics (NYSEMKT:MSTX).
KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) soaring 30% in early morning trading, adding to their 20% rise after Friday’s news that the company appointed Martin Shkreli as …
Celldex Therapeutics, Inc. (NASDAQ:CLDX) presented mature survival data from the Company’s randomized, double-blind Phase 2 study of RINTEGA® (rindopepimut) in patients with EGFRvIII-positive, …
Analysts are weighing in on the development-stage company Celldex Therapeutics, Inc. (NASDAQ:CLDX) and pharmaceutical company Lexicon Pharmaceuticals, Inc.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) presented new preclinical data on varlilumab, a fully human monoclonal agonist antibody that binds and activates CD27, a critical co-stimulatory …
Celldex Therapeutics, Inc. (NASDAQ:CLDX) reported business and financial highlights for the third quarter ended September 30, 2015.
Cowen analyst Boris Peaker was out pounding the table on Celldex Therapeutics, Inc. (NASDAQ:CLDX) Tuesday, reiterating an Outperform rating and price target of $28, which …
